Rapid detection of drug resistance and mutational patterns of extensively drug-resistant strains by a novel GenoType® MTBDRsl assay

Journal of Postgraduate Medicine

Volumn 59, Issue 3, 2013, Pages 179-185

  Singh, A K ^a   Maurya, A K ^a,b   Kant, S ^b   Umrao, J ^a   Kushwaha, R A S ^b   Nag, V L ^a   Dhole, T N ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

^b KING GEORGE'S MEDICAL UNIVERSITY   (India)

Author keywords

Extensively drug resistant; multi drug resistant; Mycobacterium tuberculosis complex

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; ETHAMBUTOL; KANAMYCIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ARTICLE; ASSAY; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG RESISTANCE; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; GENE MUTATION; GENOTYPE; INDIA; MYCOBACTERIUM TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS DRUG RESISTANCE SECOND LINE ASSAY; NONHUMAN; PHENOTYPE; SENSITIVITY AND SPECIFICITY;

AMIKACIN; ANTI-BACTERIAL AGENTS; DNA GYRASE; ETHAMBUTOL; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FLUOROQUINOLONES; GENOTYPING TECHNIQUES; HUMANS; KANAMYCIN; MUTATION; MYCOBACTERIUM TUBERCULOSIS; PENTOSYLTRANSFERASES; PHENOTYPE; RNA, RIBOSOMAL, 16S; SENSITIVITY AND SPECIFICITY;

EID: 84884653571     PISSN: 00223859     EISSN: 09722823     Source Type: Journal    
DOI: 10.4103/0022-3859.118034     Document Type: Article

References (42)

1. World Health Organization. Anti-Tuberculosis drug resistance in the world Fourth global report WHO/HTM/TB/2008394 World Health Organization, Geneva, Switzerland. 2008. [Last accessed on 2012 Aug 25].
2. Nathanson E, Nunn P, Uplekar M, Floyd K, Jaramillo E, Lonnroth K, et al. MDR tuberculosis-critical steps for prevention and control. N Engl J Med 2010;363:1050-8
3. Zignol M, Hosseini MS, Wright A, Weezenbeek CL, Nunn P, Watt CJ, et al. Global incidence of multidrug-resistant tuberculosis. J Infect Dis 2006;194:479-85
4. Maurya AK, Kant S, Kushwaha RAS, Nag VL. Extensively drug resistance Tuberculosis-New generation of drug resistance J Biosci Tech 2011;2:312-7
5. Kant S, Maurya AK, Kushwaha RA, Nag VL, Prasad R. Multi-Drug resistant tuberculosis: An iatrogenic problem. Biosci Trends 2010;4:48-55
6. Basu S, Friedland GH, Medlock J, Andrews JR, Shah NS, Gandhi NR, et al. Averting epidemics of extensively drug-resistant tuberculosis. Proc Natl Acad Sci U S A 2009;106:7672-7
7. Migliori GB, Matteelli A, Cirillo D, Pai M. Diagnosis of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: Current standards and challenges. Can J Infect Dis Med Microbiol 2008;19:169-72
8. World Health Organization. Towards universal access to diagnosis and treatment of multidrug-resistant and extensively drug-resistant tuberculosis by 2015 WHO progress report 2011 WHO/HTM/ TB/20113 World Health Organization, Geneva, Switzerland [Last accessed on 2012 Aug 15].
9. Sharma SK, George N, Kadhiravan T, Saha PK, Mishra HK, Hanif M. Prevalence of extensively drug-resistant tuberculosis among patients with multidrug-resistant tuberculosis: A retrospective hospital-based study. Indian J Med Res 2009;130:392-5
10. Datta BS, Hassan G, Kadri SM, Qureshi W, Kamili MA, Singh H, et al. Multidrug-resistant and extensively drug resistant tuberculosis in Kashmir, India. J Infect Dev Ctries 2010;4:19-23
11. Viveiros M, Leandro C, Rodrigues L, Almeida J, Bettencourt R, Couto I, et al. Direct application of the INNO-LiPA Rif.TB line-probe assay for rapid identification of Mycobacterium tuberculosis complex strains and detection of rifampin resistance in 360 smear-positive respiratory specimens from an area of high incidence of multidrug-resistant tuberculosis. J Clin Microbiol 2005;43:4880-4
12. Lacoma A, Garcia-Sierra N, Prat C, Ruiz-Manzano J, Haba L, Roses S, et al. GenoType MTBDRplus assay for molecular detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis strains and clinical samples. J Clin Microbiol 2008;46:3660-7
13. Bang D, Bengard Andersen A, Thomsen VO. Rapid genotypic detection of rifampin-And isoniazid-resistant Mycobacterium tuberculosis directly in clinical specimens. J Clin Microbiol 2006;44:2605-8
14. Hillemann D, Weizenegger M, Kubica T, Richter E, Niemann S. Use of the genotype MTBDR assay for rapid detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis complex isolates. J Clin Microbiol 2005;43:3699-703
15. Hillemann D, Rusch-Gerdes S, Richter E. Application of the Genotype MTBDR assay directly on sputum specimens. Int J Tuberc Lung Dis 2006;10:1057-9
16. Ling DI, Zwerling AA, Pai M. GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: A meta-Analysis. Eur Respir J 2008;32:1165-74
17. Somoskovi A, Dormandy J, Mitsani D, Rivenburg J, Salfinger M. Use of smear-positive samples to assess the PCR-based genotype MTBDR assay for rapid, direct detection of the Mycobacterium tuberculosis complex as well as its resistance to isoniazid and rifampin. J Clin Microbiol 2006;44:4459-63
18. Guillemin I, Jarlier V, Cambau E. Correlation between quinolone susceptibility patterns and sequences in the A and B subunits of DNA gyrase in mycobacteria. Antimicrob Agents Chemother 1998;42:2084-8
19. Antonova OV, Gryadunov DA, Lapa SA, Kuz'min AV, Larionova EE, Smirnova TG, et al. Detection of mutations in Mycobacterium tuberculosis genome determining resistance to fluoroquinolones by hybridization on biological microchips. Bull Exp Biol Med 2008;145:108-13
20. Mokrousov I, Otten T, Manicheva O, Potapova Y, Vishnevsky B, Narvskaya O, et al. Molecular characterization of ofloxacin-resistant Mycobacterium tuberculosis strains from Russia. Antimicrob Agents Chemother 2008;52:2937-9
21. van Doorn HR, An DD, de Jong MD, Lan NT, Hoa DV, Quy HT, et al. Fluoroquinolone resistance detection in Mycobacterium tuberculosis with locked nucleic acid probe real-Time PCR. Int J Tuberc Lung Dis 2008;12:736-42
22. Alangaden GJ, Kreiswirth BN, Aouad A, Khetarpal M, Igno FR, Moghazeh SL, et al. Mechanism of resistance to amikacin and kanamycin in Mycobacterium tuberculosis. Antimicrob Agents Chemother 1998;42:1295-7
23. Maus CE, Plikaytis BB, Shinnick TM. Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2005;49:3192-7
24. Maus CE, Plikaytis BB, Shinnick TM. Mutation of tlyA confers capreomycin resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2005;49:571-7
25. Plinke C, Rusch-Gerdes S, Niemann S. Significance of mutations in embB codon 306 for prediction of ethambutol resistance in clinical Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother 2006;50:1900-2
26. Safi H, Sayers B, Hazbon MH, Alland D. Transfer of embB codon 306 mutations into clinical Mycobacterium tuberculosis strains alters susceptibility to ethambutol, isoniazid, and rifampin. Antimicrob Agents Chemother 2008;52:2027-34
27. Zhang Y, Telenti A. Genetics of drug resistance in Mycobacterium tuberculosis. In: Harfull GF, Jacobs WR Jr, editors. Molecular Genetics of Mycobacteria. Washington, DC: ASM Press; 2000. p. 235-51
28. Beer J, Feldmann K, Gogolin J, Jaksch G, Kuchler R, Rifai M, et al. Evaluation of the MB/BacT drug susceptibility system for INH, RMP, SM, EMB. A cooperative study of 6 laboratories. Clin Microbiol Infect 1997;3:1086
29. Angeby KA, Werngren J, Toro JC, Hedstrom G, Petrini B, Hoffner SE. Evaluation of the BacT/ALERT 3D system for recovery and drug susceptibility testing of Mycobacterium tuberculosis. Clin Microbiol Infect 2003;9:1148-52
30. Barreto AM, Araujo JB, Medeiros RF, Caldas PC. Direct sensitivity test of the MB/BacT system. Mem Inst Oswaldo Cruz 2002;97:263-4
31. Piersimoni C, Scarparo C, Callegaro A, Tosi CP, Nista D, Bornigia S, et al. Comparison of MB/Bact alert 3D system with radiometric BACTEC system and Lowenstein-Jensen medium for recovery and identification of mycobacteria from clinical specimens: A multicenter study. J Clin Microbiol 2001;39:651-7
32. Nair D, Capoor MR, Rawat D, Srivastava L, Aggarwal P. Standardization of first and second-line antitubercular susceptibility testing using BacT Alert 3D system: A report from a tertiary care centre in India. Braz J Infect Dis 2009;13:422-6
33. Hillemann D, Rusch-Gerdes S, Richter E. Feasibility of the GenoType MTBDRsl assay for fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 2009;47:1767-72
34. Brossier F, Veziris N, Aubry A, Jarlier V, Sougakoff W. Detection by GenoType MTBDRsl test of complex mechanisms of resistance to second-line drugs and ethambutol in multidrug-resistant Mycobacterium tuberculosis complex isolates. J Clin Microbiol 2010;48:1683-9
35. Kiet VS, Lan NT, An DD, Dung NH, Hoa DV, van Vinh Chau N, et al. Evaluation of the MTBDRsl test for detection of second-line-Drug resistance in Mycobacterium tuberculosis. J Clin Microbiol 2010;48:2934-9
36. Huang WL, Chi TL, Wu MH, Jou R. Performance assessment of the GenoType MTBDRsl test and DNA sequencing for detection of second-line and ethambutol drug resistance among patients infected with multidrug-resistant Mycobacterium tuberculosis. J Clin Microbiol 2011;49:2502-8
37. Said HM, Kock MM, Ismail NA, Baba K, Omar SV, Osman AG, et al. Evaluation of the GenoType(R) MTBDRsl assay for susceptibility testing of second-line anti-Tuberculosis drugs. Int J Tuberc Lung Dis 2012;16:104-9
38. van Ingen J, Simons S, de Zwaan R, van der Laan T, Kamst-van Agterveld M, Boeree MJ, et al. Comparative study on genotypic and phenotypic second-line drug resistance testing of Mycobacterium tuberculosis complex isolates. J Clin Microbiol 2010;48:2749-53
39. Tessema B, Beer J, Emmrich F, Sack U, Rodloff AC. Analysis of gene mutations associated with isoniazid, rifampicin and ethambutol resistance among Mycobacterium tuberculosis isolates from Ethiopia. BMC Infect Dis 2012;12:37
40. Laszlo A, Rahman M, Raviglione M, Bustreo F. Quality assurance programme for drug susceptibility testing of Mycobacterium tuberculosis in the WHO/IUATLD Supranational Laboratory Network: First round of proficiency testing. Int J Tuberc Lung Dis 1997;1:231-8
41. Laszlo A, Rahman M, Espinal M, Raviglione M. WHO/IUATLD Network of Supranational Reference Laboratories. Quality assurance programme for drug susceptibility testing of Mycobacterium tuberculosis in the WHO/IUATLD Supranational Reference Laboratory Network: Five rounds of proficiency testing, 1994-1998. Int J Tuberc Lung Dis 2002;6:748-56
42. Kim SJ. Drug-susceptibility testing in tuberculosis: Methods and reliability of results. Eur Respir J 2005;25:564-9